

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1-3. (Cancelled).

4. (Original) A compound that is

3-(3-bromobenzyl)-11-methyl-1,2,3,4,5,6-hexahydro-5,2-(epiminomethano)-3-benzazocine;

3-(3-bromobenzyl)-1,2,3,4,5,6-hexahydro-5,2-(epiminomethano)-3-benzazocine;

3,11-bis(3-bromobenzyl)-1,2,3,4,5,6-hexahydro-5,2-(epiminomethano)-3-benzazocine;


11-acetyl-3-(3-bromobenzyl)-1,2,3,4,5,6-hexahydro-5,2-(epiminomethano)-3-benzazocine;

or a pharmaceutically acceptable salt or stereoisomer thereof.

5. (Previously Presented) A pharmaceutical composition which is comprised of a compound in accordance with Claim 21 and a pharmaceutically acceptable carrier.

6-20. (Cancelled).

21. (Currently Amended) A compound of Formula II



wherein:

R<sup>1</sup> is independently selected from

- 1) H,
- 2) halo,
- 3) OR<sup>4</sup>,
- 4) NO<sub>2</sub>,
- 5) -S(O)<sub>m</sub>R<sup>4</sup>,
- 6) CN
- 7) unsubstituted or substituted C<sub>1</sub>-C<sub>10</sub> alkyl,
- 8) unsubstituted or substituted aryl,
- 9) unsubstituted or substituted C<sub>2</sub>-C<sub>6</sub> alkenyl,
- 10) unsubstituted or substituted C<sub>3</sub>-C<sub>10</sub> cycloalkyl,
- 11) unsubstituted or substituted C<sub>2</sub>-C<sub>6</sub> alkynyl,
- 12) unsubstituted or substituted heterocycle,
- 13) -C(O)R<sup>4</sup>,
- 14) C(O)OR<sup>4</sup>,
- 15) C(O)N(R<sup>4</sup>)<sub>2</sub>,
- 16) S(O)<sub>m</sub>N(R<sup>4</sup>)<sub>2</sub>, and
- 17) N(R<sup>4</sup>)<sub>2</sub>;

R<sup>2</sup> is selected from

- 1) H,
- 2) C<sub>1</sub>-C<sub>6</sub> alkyl, and
- 3) (C=O)C<sub>1</sub>-C<sub>6</sub> alkyl,

wherein said alkyl is optionally substituted with phenyl wherein said phenyl is optionally substituted with halo;

R<sup>3</sup> is

- 1) C<sub>1</sub>-C<sub>6</sub> alkyl

wherein said alkyl is optionally substituted with phenyl wherein said phenyl is optionally substituted with halo;

R<sup>4</sup> is independently selected from

- 1) H,
- 2) unsubstituted or substituted C<sub>1</sub>-C<sub>10</sub> alkyl,
- 3) unsubstituted or substituted C<sub>3</sub>-C<sub>10</sub> cycloalkyl,
- 4) unsubstituted or substituted aryl,
- 5) unsubstituted or substituted heterocycle, and
- 6) CF<sub>3</sub>;

m is independently 0, 1 or 2;

s is 1 to 4;

or a pharmaceutically acceptable salt or stereoisomer thereof.

22. (New) A method of treating gliomas, meningomas, colon cancer, gastric cancer, pancreatic cancer, esophageal cancer, hepatocellular cancer, lung (small cell and non-small cell) cancer, thyroid cancer, breast cancer, ovarian cancer, endometrial cancer, vaginal cancer, cervical cancer, prostate cancer, testicular cancer, renal cell cancer, bladder cancer, osteosarcoma, chondrosarcoma, melanoma, basal cell carcinoma, Hodgkin's disease and retinal vascularization in a mammal in need of such treatment comprising administering to said mammal a therapeutically effective amount of a compound of Claim 21.